Cargando…
Sources of Heterogeneity in Trials Reporting Hydroxyethyl Starch 130/0.4 or 0.42 Associated Excess Mortality in Septic Patients: A Systematic Review and Meta-regression
BACKGROUND: This meta-analysis was to determine the association of the cumulative dose of 130/0.4 or 0.42 (hydroxyethyl starch [HES] 130/0.4*) or delta daily fluid balance (i.e., daily fluid balance in HES group over or below control group) with the heterogeneity of risk ratio (RR) for mortality in...
Autores principales: | Ma, Peng-Lin, Peng, Xiao-Xia, Du, Bin, Hu, Xiao-Lan, Gong, Yi-Chun, Wang, Yu, Xi, Xiu-Ming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4733795/ https://www.ncbi.nlm.nih.gov/pubmed/26315087 http://dx.doi.org/10.4103/0366-6999.163387 |
Ejemplares similares
-
Low-quality Trials as a Source of Heterogeneity in the Association of Hydroxyethyl Starch 130/0.4 or 0.42 with Excess Mortality in Sepsis
por: Wiedermann, Christian J
Publicado: (2016) -
The impact of 30 ml/kg hydroxyethyl starch 130/0.4 vs hydroxyethyl starch 130/0.42 on coagulation in patients undergoing abdominal surgery
por: Staikou, Chryssoula, et al.
Publicado: (2012) -
Is hydroxyethyl starch 130/0.4 safe?
por: Haase, Nicolai, et al.
Publicado: (2012) -
Hydroxyethyl starch 200/0.5 induces more renal macrophage infiltration than hydroxyethyl starch 130/0.42 in an isolated renal perfusion model
por: Hüter, L, et al.
Publicado: (2008) -
Hydroxyethyl starch 130/0.42/6:1 for perioperative plasma volume replacement is safe and effective in children
por: Suempelmann, R, et al.
Publicado: (2008)